EZH2 and brain neoplasm: Subsequent preclinical studies demonstrated therapeutic potential in variety of pediatric CNS tumors, such as MB with wild type p53, AT/RT, or HGG, supporting further evaluation in pediatric brain tumors with EZH2 overexpression, though combination strategies may be needed to overcome resistance and intratumoral heterogeneity (198, 217).